11.04.10

Ricerca Biosciences Announces Senior Scientific and Operational Leadership in Drug Safety, Douglas K. Fuhrer, Ph.D., DABT

(Concord, OH; November 4, 2010) – Ricerca Biosciences, a preclinical development contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the addition of Douglas K. Fuhrer, Ph.D., DABT, as senior director of drug safety.

Dr. Fuhrer has over 12 years experience directing teams of scientists and technicians in large pharmaceutical companies, biotech organizations and CROs. His training and experience includes applied animal investigation skills, serving as a study director of toxicology and safety pharmacology Good Laboratory Practice (GLP) studies and completing multiple successful INDs and non-clinical programs supporting clinical development. His expertise lies within many therapeutic areas including anti-infectives, cancer, immune regulation, diabetes, CNS, prostate enlargement and hepatitis C.

“Doug is an extremely strong addition to our Preclinical Development Leadership Team,” stated Dr. Michael Placke, senior vice president and general manager of Ricerca’s Concord, Ohio, drug development operations. “Doug possesses the experience and insights necessary to guide our preclinical drug development strategies.”

Dr. Fuhrer received both a Bachelor of Science and Master of Science in biological sciences from Northern Illinois University and a Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign. He is board certified in toxicology (DABT) and is a member of the Society of Toxicology (SOT), Safety Pharmacology Society (SPS) and American Association of Pharmaceutical Scientists (AAPS).

Ricerca offers a unique spectrum of services for the areas of preclinical discovery and chemical synthesis development for pharmaceutical and biopharmaceutical products, as well as agrochemical and environmental registration.

About Ricerca Biosciences
Ricerca Biosciences, LLC, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S. based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon and Bothell facilities also hold AAALAC certification.